4:21 PM
 | 
Sep 13, 2013
 |  BC Extra  |  Company News

FDA to discuss Gilead's sofosbuvir

FDA's Antiviral Drugs Advisory Committee will meet on Oct. 25 to discuss an NDA from Gilead Sciences Inc. (NASDAQ:GILD) for sofosbuvir ( GS-7977) to treat chronic HCV infection....

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >